Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities
Bioorganic Chemistry · 2023
DOI: 10.1016/j.bioorg.2023.106580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Jian Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhengzhou University.
Abstract (Originalsprache)
As a class of microtubule targeting agents, colchicine binding site inhibitors (CBSIs) are considered as promising drug candidates for cancer therapy. However, due to adverse reactions, there are currently no CBSIs approved by FDA for cancer treatment. Therefore, extensive efforts are still encouraged to find novel CBSIs with different chemical structures and better anticancer efficacies. In this work, we designed and synthesized a new coumarin-dihydroquinoxalone derivative, MY-673, and evaluated its anticancer potency in vitro and in vivo. We confirmed that MY-673 was a potent CBSI that it not only inhibited tubulin polymerization, but also exhibited significant inhibitory potency on the growth of 13 cancer cells with IC50 values from 11.7 nM to 395.9 nM. Based on the results of kinase panel screening, MY-673 could inhibit ERK (extracellular regulated protein kinases) pathways-related kinases. We further confirmed that MY-673 could inhibit ERK signaling pathway in MGC-803 and HGC-27 cells, and then affected the expression level of SMAD4 protein in TGF-β (transforming growth factor β) /SMAD (small mother against decapentaplegic) signaling pathway using the western blotting assay. In addition, compound MY-673 could effectively inhibit cell proliferation, migration and induce cell apoptosis. We also further confirmed the in vivo efficacy of MY-673 in inhibiting tumor growth using the MGC-803 xenograft tumor model. At 20 mg/kg, the TGI rate was 85.9%, and it did not cause obvious toxicity to the main organs of mice. Together, the results we report here indicated that MY-673 was a promising CBSI for cancer treatment, which was capable of inhibiting the ERK pathway with potent antiproliferative activities in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
- School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advanced Drug Preparation Technologies (Ministry of Education), Zhengzhou University, Zhengzhou, Henan 450001, China.
- School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advanced Drug Preparation Technologies (Ministry of Education), Zhengzhou University, Zhengzhou, Henan 450001, China. Elect…
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China; School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advance…
Förderung
- National Natural Science Foundation of China
- Zhengzhou University
Zitieren
APA
Song, J., Wang, S. Y., Wang, X., Jia, M. Q., Tian, X. Y., Fu, X. J., Jin, C. Y., & Zhang, S. Y. (2023). Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106580
Vancouver
Song J, Wang SY, Wang X, Jia MQ, Tian XY, Fu XJ, et al. Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106580
BibTeX
@article{Song2023,
author = {Song, Jian and Wang, Shu-Yu and Wang, Xiao and Jia, Mei-Qi and Tian, Xin-Yi and Fu, Xiang-Jing and Jin, Cheng-Yun and Zhang, Sai-Yang},
title = {Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities},
journal = {Bioorganic Chemistry},
year = {2023},
doi = {10.1016/j.bioorg.2023.106580}
}
EUVIMED